Brian Park, PharmD

Drug Information Specialist https://www.clinicaladvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Hematology Information Center

Monoferric Injection Approved for Iron Deficiency Anemia

Brian Park, PharmD

February 26, 2020

Monoferric will be supplied in 100mg/mL, 500mg/5mL, and 1000mg/10mL single-dose vials for intravenous infusion after dilution.

Vaccine Information Center

ACIP: 2020 Adult Immunization Schedule Updates

Brian Park, PharmD

February 10, 2020

The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has released an updated version of the adult immunization schedule for ages 19 years and older in the United States.

Allergy and Immunology Information Center

FDA Approves First Treatment for Peanut Allergy

Brian Park, PharmD

February 4, 2020

The Food and Drug Administration (FDA) has approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp; Aimmune Therapeutics) for the treatment of peanut allergy.

Rheumatology Information Center

Updated Guideline for the Management of Osteoarthritis Released

Brian Park, PharmD

January 10, 2020

In addition to a panel of experts, for the first time, the guideline was developed with the help of patients, emphasizing the importance of shared decision-making.

Sleep Information Center

FDA Approves Wakix For Excessive Daytime Sleepiness In Adults With Narcolepsy

Brian Park, PharmD

December 31, 2019

The Food and Drug Administration (FDA) approved Wakix for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.

Neurology Information Center

ALS Treatment Approved for Use Via Percutaneous Endoscopic Gastrostomy Tubes

Brian Park, PharmD

December 24, 2019

The FDA has approved the supplemental New Drug Application for Tiglutik oral suspension to include administration via percutaneous endoscopic gastrostomy (PEG) tubes for the treatment of amyotrophic lateral sclerosis.

Diabetes Information Center

Toujeo Approved for Pediatric Patients With Diabetes

Brian Park, PharmD

December 13, 2019

The FDA has expanded the indication for Toujeo (insulin glargine; Sanofi) 300 Units/mL to include treatment of pediatric patients aged ≥6 years with diabetes mellitus.

Infectious Diseases Information Center

App Allows Clinicians to Report on New Uses of FDA-Approved Drugs for Difficult-to-Treat Infectious Diseases

Brian Park, PharmD

December 10, 2019

The Food and Drug Administration (FDA) has launched CURE ID, an internet-based repository that allows clinicians to report their experiences using existing FDA-approved drugs for difficult-to-treat infections.

Should Prescription Drugs Become OTC? Two Experts Weigh In

Practice Management Information Center

FDA: Dollar Tree Stores May Be Selling Potentially Harmful OTC Products

Brian Park, PharmD

November 19, 2019

The Food and Drug Administration (FDA) has issued a warning letter to Greenbrier International for receiving over-the-counter (OTC) drugs produced by foreign manufacturers with multiple violations of current good manufacturing practices (CGMP).

ADHD Information Center

Viloxazine NDA Submitted for Review as Potential New ADHD Treatment

Brian Park, PharmD

November 18, 2019

The New Drug Application (NDA) for viloxazine hydrochloride (SPN-812; Supernus Pharmaceuticals), a serotonin norepinephrine modulating agent, has been submitted to the Food and Drug Administration (FDA) for the treatment of pediatric patients with attention deficit hyperactivity disorder (ADHD).

Next post in ADHD Information Center